Brisbane, Australia, 19 August 2022 – ResApp Health Limited...

Brisbane, Australia, 19 August 2022 – ResApp Health Limited (ASX: RAP) (ResApp) refers to its
previous announcement entitled “Best and Final Confirmation and Bridging Loan” made on 16
August 2022 (Announcement) in relation to the proposed acquisition of ResApp by Pfizer
Australia Holdings Pty Limited (a wholly-owned subsidiary of Pfizer Inc., a global
biopharmaceutical company) (Pfizer) by way of a scheme of arrangement (Scheme).
The announcement disclosed the key terms of a loan agreement pursuant to which Pfizer has
agreed to provide A$680,000 to ResApp to enable ResApp to meet its short-term working capital
needs during the Scheme period (Bridging Loan).
ResApp wishes to correct the description of the Bridging Loan in the Announcement such that the
period for remediation of an event of default after receipt of a default notice from Pfizer is in fact
5 business days rather than 10 business days (as was previously disclosed)